ReviewJournal of personalized medicine2022
From Skin Barrier Dysfunction to Systemic Impact of Atopic Dermatitis: Implications for a Precision Approach in Dermocosmetics and Medicine.
Review in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Future Integration of Biomarkers for Inflammatory Skin Diseases Into Daily Practice: A Survey Among a Multifaceted Group of Patients and Dermatological Care Providers.Experimental dermatology · 2026Article
- Gestational Diabetes Mellitus Increases the Risk of Atopic Dermatitis in Children: A National Retrospective Study with Analysis by Treatment Modality.Dermatology and therapy · 2026Article
- The potential of targeted IL-4 therapy for the comorbidity of atopic dermatitis and attention-deficit/hyperactivity disorder in children via the skin-brain axis.Frontiers in allergy · 2026Article
- Atopic dermatitis and fecundity: a Danish National Birth Cohort study.Human reproduction open · 2026Article
- The Mechanisms of Immunoglobulin E Sensitizations in Atopic Dermatitis.Immunology and allergy clinics of North America · 2025Review
- Unlocking the molecular pathway of atopic dermatitis: journey so far and roads ahead.Inflammopharmacology · 2025Review
- Tripeptide-Loaded Liposomes as Multifunctional Components in Topical Formulations.International journal of molecular sciences · 2025Article
- Review
- A Prospective Open-Label Study of Tolerance and Effectiveness of Sequential Dermocosmetic Treatments Combining Poly-l-Lysine Biovectors With Vitamins A and C.Health science reports · 2025Article
- Comprehensive analysis of protective effects ofAnimal cells and systems · 2025Article
- Soothing the Itch: The Role of Medicinal Plants in Alleviating Pruritus in Palliative Care.Plants (Basel, Switzerland) · 2024Review
- Advanced Systemic Treatments in Patients with Moderate-to-Severe Atopic Dermatitis: Key Learnings from Physicians Practicing in Nine Asian Countries and Territories.Dermatology and therapy · 2024Article
- Primary Prevention of Canine Atopic Dermatitis: Breaking the Cycle-A Narrative Review.Veterinary sciences · 2023Review
- Type 2 chronic inflammatory diseases: targets, therapies and unmet needs.Nature reviews. Drug discovery · 2023Review
- Disease modification in inflammatory skin disorders: opportunities and challenges.Nature reviews. Drug discovery · 2023Review
- Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis.Pharmaceutics · 2023Review
- Skin-associated adipocytes in skin barrier immunity: A mini-review.Frontiers in immunology · 2023Review
- Emollients "Plus" are Beneficial in Both the Short and Long Term in Mild Atopic Dermatitis.Clinical, cosmetic and investigational dermatology · 2023Article
- Dermatologic Disease-Directed Targeted Therapy (DDermatology and therapy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
Abstract
Atopic dermatitis (AD) affects up to 20% of children and is considered the starting point of the atopic march with the development of food allergy, asthma, and allergic rhinitis. The heterogeneous phenotype reflects distinct and/or overlapping pathogenetic mechanisms with varying degrees of epidermal barrier disruption, activation of different T cell subsets and dysbiosis of the skin microbiome. Here, we review current evidence suggesting a systemic impact of the cutaneous inflammation in AD together with a higher risk of asthma and other comorbidities, especially in severe and persistent AD. Thus, early therapy of AD to restore the impaired skin barrier, modified microbiome, and target type 2 inflammation, depending on the (endo)phenotype, in a tailored approach is crucial. We discuss what we can learn from the comorbidities and the implications for preventive and therapeutic interventions from precision dermocosmetics to precision medicine. The stratification of AD patients into biomarker-based endotypes for a precision medicine approach offers opportunities for better long-term control of AD with the potential to reduce the systemic impact of a chronic skin inflammation and even prevent or modify the course, not only of AD, but possibly also the comorbidities, depending on the patient's age and disease stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.